Amarin Shares Sink on Secondary Offering

"More means less." Amarin (NASDAQ: AMRN  ) demonstrated this seemingly contradictory maxim today following its announcement of a new public offering. Shares promptly sank by 8%. With more shares on the market, the less each share is worth. Let's take a look at the details.

Adding up the ADSs
Amarin plans to sell 21.7 million American Depositary Shares, or ADSs, in a public offering. The underwriters of the sale will also have a 30-day option to purchase another 3.255 million shares. The shares will be offered at prevailing market prices.

There are currently 150.7 million or so outstanding shares of Amarin's stock. This new offering represents around 14% of outstanding shares, with the option available to underwriters making up another 2%. In one sense, a drop of only 8% with potential share dilution of twice as much doesn't sound too bad. 

As of the end of March, Amarin had cash and equivalents of a little more than $203 million. Why have another public offering now? The company wants to use the proceeds generated to fund its continued commercial launch of triglyceride-lowering drug Vascepa. At the current pace it's burning through cash, Amarin will need more in 2014. It's better to take care of business sooner rather than later.

Tale of two charts
Amarin's recent history is basically a tale of two charts. The company's decision to launch Vascepa on its own has taken a toll on its stock. However, the good news is that Vascepa sales have been climbing. 

AMRN Chart

AMRN data by YCharts.

Source: Company SEC filing. 

It should be noted that the June prescription number for Vascepa comes with a couple of caveats from the company. The last two days of the month aren't included in the total. Also, the figure is based on weekly compilations of data, which Amarin says tend to understate the number obtained later in the monthly compilation.

Why have share prices continued to fall at the same time that Vascepa sales have grown? In large part, the answer boils down to skepticism. 

Many are skeptical about Amarin's ability to successfully commercialize Vascepa to its full potential against larger competitors with fish-oil pills. GlaxoSmithKline (NYSE: GSK  ) markets Lovaza and has made nearly $3.8 billion from the drug over the last five years. AstraZeneca (NYSE: AZN  ) bought Omthera Pharmaceuticals in May, primarily to gain its fish-oil drug Epanova.

Some are skeptical about Amarin's prospects for obtaining approval to sell Vascepa for treating individuals who have triglyceride levels between 200 and 500 mg/dL. While the drug is approved for people with very high triglyceride levels, the market for this lower-yet-still-high triglyceride level range is 10 times larger.

There is also skepticism in the physician and payer community about the real health benefits of prescription fish-oil drugs. Several clinical studies have had less-than-stellar results.

To be fair, though, studies of Vascepa showed solid results in lowering triglyceride levels. Unlike Glaxo's Lovaza, it did so without raising cholesterol levels. And while analysts expect Lovaza sales to decline this year, Amarin continues to report higher sales for Vascepa.

AstraZeneca and Omthera only recently submitted a New Drug Application for Epanova in treating patients with very high triglyceride levels of 500 mg/dL and above. Meanwhile, Amarin moves ahead with marketing to that patient population while it awaits possible approval for a much-larger market. A decision by the Food and Drug Administration is scheduled for Dec. 20. 

Foolish take
I suspect that the company will continue to report increasing Vascepa sales numbers. There also appears to be a reasonable chance that the FDA will approve the drug for individuals with high (as opposed to very high) triglyceride levels later this year. Amarin's shares could very well be much higher by year end.

For now, though, I'd recommend a "more means less" strategy. Wait for a little more certainty about the market for Vascepa -- and take less profit.

Like many biotech and pharmaceutical stocks, Amarin carries considerable risk. Of course, it also brings the potential for significant rewards in exchange. It's good for investors to balance stocks like Amarin with others that have less risk, like solid dividend stocks. If you're on the lookout for high-yielding stocks, The Motley Fool has compiled a special free report outlining our nine top dependable dividend-paying stocks. It's called "Secure Your Future With 9 Rock-Solid Dividend Stocks." You can access your copy today at no cost! Just click here.

Read/Post Comments (1) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On July 09, 2013, at 2:56 PM, ralpheyralph wrote:

    This is one of the best buying opportunities I have seen.

    VAscepa is the best drug in class - period . AS MD's become aware that Lovaza increases LDL by 45% all of those Rx's will be transferred to Vascepa.

    THe ANCHOR trial is a moot point. LOvaza could not be used for Triglyceriedes between 250 and 500 as it raises LDL by 45% and LDL is considered to be the major atherogenic (causing blockage of arteries leading to heart attacks and strokes). SO it would makes little sense to lower triglycerides while raise LDL by 45%.

    AS a matter of fact I am waiting for the lawyers commericals .

    " HAve you taken Lovaza and had a heart attack? If so call 1800 bad bad drug!"

    Vascepa on the other hand does not increase ldl it actually lowers it - so there is no worry about using it for individuals with triglycerides between 250 - 500 regardless of the ANCHOR study it is now being used in that arena

    Best Drug in class - Period will at least take over most of lovaza's rx's and gain many new ones for patients in the trig level of 250 - 500

    Thats a winner - its simply a matter of time

Add your comment.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2528413, ~/Articles/ArticleHandler.aspx, 9/30/2016 1:00:38 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated 3 hours ago Sponsored by:
DOW 18,143.45 -195.79 -1.07%
S&P 500 2,151.13 -20.24 -0.93%
NASD 5,269.15 -49.39 -0.93%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

9/29/2016 4:00 PM
AMRN $3.13 Down -0.11 -3.40%
Amarin CAPS Rating: ****
AZN $33.05 Down -0.77 -2.28%
AstraZeneca CAPS Rating: ****
GSK $42.90 Down -0.77 -1.76%
GlaxoSmithKline CAPS Rating: ***